Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Carcinoma, Non-small-cell Lung

In brief

The purpose of this study is to determine the effectiveness of TLK286 in the treatment of advanced non-small cell lung cancer.

Key facts

Study ID

NCT00040638

Run by

Telik

People needed

40

Starts

2002-07-01

Expected to finish

2003-08-01

Last updated by the study team

2011-07-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic or cytologic diagnosis of non-small cell lung carcinoma
• Progressed while on or after treatment on platinum-based regimen
• Patients may not have had more than one prior cytotoxic chemotherapy regimen
• Stage IV or IIIB
• Age at least 18 years
• Adequate liver and kidney function
• Adequate bone marrow function

You may not qualify if…

• Pregnancy or lactation
• Unstable medical conditions
• Chemotherapy, hormonal therapy, radiotherapy, radiopharmaceuticals or immunotherapy within 3 weeks of TLK286
• CNS metastasis unless controlled by treatment

Where it is running

• Arizona Cancer Center — Tucson, Arizona, United States
• UCLA Medical Center — Los Angeles, California, United States
• M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.